HUMBL Announces Purchase of HUMBL Financial by Avrio, to Drive a Range of Financial Products and Services into the Global Markets
29 févr. 2024 09h00 HE
|
HUMBL, Inc.
New York, San Diego, London, Abu Dhabi, Feb. 29, 2024 (GLOBE NEWSWIRE) -- HUMBL, Inc. (OTC: HMBL) and Avrio are pleased to announce the acquisition of the HUMBL Financial brand, products and...
Avrio announces strategic investment from DLMI to secure its registered digital financial market infrastructure for the tokenization of digital assets across the DLMI network of companies
20 févr. 2024 07h18 HE
|
AVRIO Worldwide
NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Avrio Worldwide, PBC (Avrio) announces Diamond Lake Minerals, Inc., (OTC: DLMI) has made a strategic investment in Avrio to deploy its registered digital...
Avrio Announces The Appointment of Co-Founder Lawrence Wintermeyer as CEO
16 févr. 2024 08h51 HE
|
AVRIO Worldwide
NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Avrio Worldwide (Avrio) has announced that it has appointed co-founder Lawrence Wintermeyer as CEO. Wintermeyer has held roles chairing regulated...
Avrio Announces its Digital Financial Market Infrastructure for business is now available in the Abu Dhabi Global Markets Financial Services Regulatory Authority Digital Lab
05 déc. 2023 08h10 HE
|
AVRIO Worldwide
NEW YORK and LONDON and ABU DHABI, United Arab Emirates, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Avrio has announced that its Digital Financial Market Infrastructure (DFMI) is now available in the Abu...
Hemispherx Biopharma Announces Completion of Ampligen® Manufacturing Technology Transfer Milestone
19 oct. 2016 08h30 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Oct. 19, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the "Company") announced today that it has completed its technology transfer of the Ampligen®...
Hemispherx Biopharma Reaches Agreement with Avrio Biopharmaceuticals for the Accelerated Production of Ampligen®
27 juil. 2016 08h30 HE
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 27, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) ("Hemispherx" or the “Company") announced today that it has reached an agreement with Avrio Biopharmaceuticals...